Thursday, 20 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 3, 2026

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

View original at globenewswire.com
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expe…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Today's acquisition validates our team's vision and approach

    80% confidence

  • This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion's momentum and advances our long-term Vision 2040

    80% confidence

  • The transaction is expected to close in the second quarter of 2026

    80% confidence

  • Enbumyst addresses a U.S. market with a potential opportunity exceeding $4 billion

    80% confidence

  • The availability of an FDA-approved intranasal diuretic like Enbumyst represents an important therapeutic advance offering potential for more flexible, rapid, and patient-friendly fluid management that can be done at home

    80% confidence

  • Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy

    80% confidence

  • Edema and congestion remain the most burdensome and persistent symptoms for patients living with heart failure, often driving hospitalizations, impairing quality of life, and complicating day-to-day disease management

    80% confidence

  • There are an estimated 6.7 million American adults living with CHF

    80% confidence

  • Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need

    80% confidence

  • By integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all stakeholders

    80% confidence

Cited in these Via News reports